Core Viewpoint - The AI Fund Jiashi Healthcare Stock (000711) reported a profit of 128 million yuan for the first half of 2025, with a weighted average profit per fund share of 0.2917 yuan. The fund's net value growth rate was 17.67%, and the fund size reached 825 million yuan by the end of the first half of the year [2]. Fund Performance - As of September 3, the fund's unit net value was 2.349 yuan. The fund manager, Hao Miao, has managed three funds with positive returns over the past year. Among these, Jiashi Mutual Selection Stock A had the highest one-year growth rate at 118.85%, while Jiashi Healthcare Stock had the lowest at 54.44% [2]. - The fund's net value growth rates over different periods are as follows: 22.73% over the last three months, 31.38% over the last six months, 54.44% over the last year, and -0.93% over the last three years [5]. Market Outlook - The fund management anticipates a resilient global economy and continued improvement in domestic macro expectations, suggesting that there is still room for investment in the capital market. The healthcare sector is viewed as having reasonable valuations with several stock opportunities worth exploring [2]. Valuation Metrics - As of June 30, 2025, the fund's weighted average price-to-earnings (P/E) ratio was approximately 61.56 times, compared to a negative average of -135.64 times for similar funds. The weighted average price-to-book (P/B) ratio was about 3.66 times, while the average for similar funds was 4.24 times [10]. - The weighted average revenue growth rate for the fund's held stocks was 0.06%, and the weighted average net profit growth rate was 0.14% for the first half of 2025 [18]. Fund Composition - As of June 30, 2025, the fund had a total of 50,300 holders, with a total of 427 million shares held. Individual investors accounted for 99.70% of the holdings, while management and institutional investors held 0.07% and 0.30%, respectively [34]. - The fund's top ten holdings have consistently represented over 60% of the total assets for nearly two years, with major stocks including Haoyuan Pharmaceutical, Zexing Pharmaceutical, and Hengrui Medicine [39].

Company News - Sun Hung Kai Properties (00016.HK) reported a revenue of HKD 79.721 billion for the fiscal year 2025, an increase of 11.5% year-on-year; net profit reached HKD 19.277 billion, up 1.2% year-on-year [2] - Sincere Watch International (00732.HK) recorded a net operating revenue of approximately HKD 11.011 billion for the first eight months, a decrease of 5.5% year-on-year; in August, the net operating revenue was about HKD 1.445 billion, down 6.5% year-on-year [2] Financial Activities - China Construction Bank (00939.HK) announced that CCB Financial Leasing plans to increase its capital by HKD 3 billion to CCB Shipping and Aviation [3] Pharmaceutical Developments - Heng Rui Medicine (01276.HK) received approval to conduct clinical trials for RSS0393 ointment, which can alleviate tissue damage and inflammation related to atopic dermatitis [4] - Heng Rui Medicine (01276.HK) also received approval for clinical trials of HRS-4729 injection, a tri-agonist for GLP-1R/GIPR/GCGR [4] Real Estate Sales Performance - China Overseas Land & Investment (00688.HK) reported a contracted sales amount of HKD 150.331 billion for the first eight months, a decline of 16.5% year-on-year; August contracted sales were HKD 18.33 billion, down 0.7% year-on-year [5] - Sunac China (01918.HK) recorded a contracted sales amount of approximately HKD 30.47 billion for the first eight months, a decrease of 13% year-on-year; August contracted sales were HKD 5.39 billion, down 26.7% year-on-year [5] - China Overseas Grand Oceans Group (00081.HK) reported a contracted sales amount of HKD 20.783 billion for the first eight months, a decline of 10.6% year-on-year; August contracted sales were HKD 2.133 billion, an increase of 6.1% year-on-year [5] - Gemdale Corporation (00535.HK) reported a total contracted sales of approximately HKD 7.588 billion for the first eight months, a decrease of 39% year-on-year; August contracted sales were HKD 608 million, down 52.9% year-on-year [5] - Hongyang Real Estate (01996.HK) reported a contracted sales amount of HKD 3.506 billion for the first eight months, a decrease of 42.2% year-on-year; August contracted sales were HKD 299 million, down 48.5% year-on-year [5] - Ronshine China Holdings (03301.HK) reported a contracted sales amount of approximately HKD 2.7 billion for the first eight months, a decline of 46.4% year-on-year; August contracted sales were about HKD 130 million, down 87.9% year-on-year [5] Share Buyback Activities - HSBC Holdings (00005.HK) repurchased 2.01 million shares at a cost of approximately HKD 200 million, with prices ranging from HKD 98.75 to HKD 100.3 [6] - Midea Group (00300.HK) repurchased 310,000 shares at a cost of approximately HKD 25.849 million, with prices ranging from HKD 83.3 to HKD 83.5 [6] - Hang Seng Bank (00011.HK) repurchased 210,000 shares at a cost of approximately HKD 23.799 million, with prices ranging from HKD 112.9 to HKD 113.7 [6] - MGM China Holdings (02282.HK) repurchased 1 million shares at a cost of approximately HKD 15.687 million, with prices ranging from HKD 15.58 to HKD 15.97 [6] Shareholding Changes - Kanglong Chemical (03759.HK) completed a share reduction plan, with a total of 26.6729 million shares reduced [6] - Sinopec Limited (00386.HK) canceled 67.624 million shares that had been repurchased [6]

Group 1 - The company 康龙化成 has received a notification letter from 信中康成 and its concerted party 深圳市信中龙成投资合伙企业 regarding the completion of a share reduction plan [1] - 信中康成 has cumulatively reduced its holdings by 26.6729 million shares [1]

Group 1 - The core point of the article is that 康龙化成 (Kanglong Chemical) has received a notification from 信中康成 (Xinchong Kangcheng) and its associated party, 深圳市信中龙成投资合伙企业 (Shenzhen Xinchong Longcheng Investment Partnership), regarding the completion of a share reduction plan [1] - 信中康成 has cumulatively reduced its holdings by 26.6729 million shares [1]

Group 1 - The core point of the article is that Kanglong Chemical (SZ 300759) announced the completion of a share reduction plan by its shareholder, Xincheng Kangcheng, who reduced approximately 26.67 million shares, accounting for 1.50% of the company's total shares [1] - As of the report date, Kanglong Chemical's market capitalization is 52.7 billion yuan [2] - For the year 2024, Kanglong Chemical's revenue composition is primarily from scientific research and technical services, which accounts for 99.95%, while other businesses contribute only 0.05% [1]

Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 海外監管公告 本公告乃康龍化成（北京）新藥技術股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條作出。 茲載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 中華人民共和國，北京 2025年9月4日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事萬璇女士及李家慶先生；獨立非執行董事李麗華女士、曾坤鴻先生及余堅 先生。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于 2025 年 5 月 16 日在巨潮资讯网（www.c ...

本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于 2025 年 5 月 16 日在巨潮资讯网（www.cninfo.com.cn）披露了《关于持股 5%以上股东减 持股份的预披露公告》（公告编号：2025-027）。公司持股 5%以上股东深圳市 信中康成投资合伙企业（有限合伙）（以下简称"信中康成"）计划自上述减持 公告披露之日起 15 个交易日（2025 年 6 月 10 日）后的 3 个月内以集中竞价交 易或大宗交易等深圳证券交易所认可的合法方式减持公司股份不超过 26,672,932 股（占公司总股本的 1.50%）。 公司于近日收到信中康成和其一致行动人深圳市信中龙成投资合伙企业（有 限合伙）（以下简称"信中龙成"）出具的告知函，获悉信中康成本次减持计划 已实施完毕，现将减持计划实施情况公告如下： 一、股东减持情况 证券代码：300759 证券简称：康龙化成 公告编号：2025-050 康龙化成（北京）新药技术股份有限公司 关于持股 5%以上股东减持计划实施完成的公告 公司持股 5%以上股东深圳市信中康成投资合伙企业（有限合 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | ...

Market Overview - On September 4, the medical services sector declined by 4.28%, with Bid Pharma leading the drop [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Stock Performance - Notable gainers in the medical services sector included: - Zihua Pharmaceutical (600721) with a closing price of 11.07, up 6.24% [1] - Innovation Medical (002173) with a closing price of 24.99, up 5.31% [1] - Wisdom Pharmaceutical (300149) with a closing price of 13.17, up 4.36% [1] - Major decliners included: - Bid Pharma (688073) with a closing price of 62.65, down 9.44% [2] - WuXi AppTec (603259) with a closing price of 101.94, down 8.06% [2] - Zhaoyan New Drug (603127) with a closing price of 30.92, down 7.48% [2] Capital Flow - The medical services sector experienced a net outflow of 1 billion yuan from institutional investors, while retail investors saw a net inflow of 359 million yuan [2][3] - Key stocks with significant capital flow included: - Innovation Medical (002173) with a net inflow of 136 million yuan from institutional investors [3] - Wisdom Pharmaceutical (300149) with a net inflow of 79 million yuan from institutional investors [3] - Meinian Health (002044) with a net inflow of 64 million yuan from institutional investors [3]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | 2. 股份分類 | 普通股 ...